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Recent studies on mice genetically modified at the Ahr locus and fed on high-fat diet have
revealed a novel physiological role for the AHR in energy balance. Globally impaired function of
the receptor counteracts the development of obesity by increasing energy expenditure, which
appears to occur mostly in the skeletal muscle and brown adipose tissue. On the other hand,
global and tissue-specific loss of AHR signaling can have opposite effects on liver fat content and
their impact on insulin sensitivity is also context-dependent. As tryptophan metabolites are key
AHR activators, these findings suggest that the AHR may act as a protein sensor enabling adequate
protein intake from low-protein diets by allowing calorie overfeeding without resultant obesity.
Introduction
One of the most characteristic and conspicuous signs of the acute toxicity of TCDD, an extremely
potent agonist of the AHR, is the wasting syndrome, which is especially pronounced in the rat and
denotes a profound body weight loss (up to over 50% of initial body weight) before death ensues.
It primarily results from reduced feed intake [1,2]. The fact that this dramatic response did not
appear to be due to nausea or malaise [3] suggested a specific impact on the regulation of energy
balance or body weight.  This view was reinforced by the findings that rats treated with sublethal
doses of TCDD defended their lowered body weight level against external manipulation attempts
by even exhibiting hyperphagia if necessary [4], and that TCDD exposure appeared to permanently
imprint peculiar deviations on rats’ feeding behavior and responses to feeding regulatory
challenges [5-7]. Moreover, female C3H/HeN mice treated with a high dose of TCDD (100 µg/kg,
once every 2 weeks for 8 weeks) and fed on a high-fat diet surprisingly exhibited augmented body
gain compared with their vehicle-treated controls on the same diet [8]. Thus, it was somewhat
disappointing to find out that genetic deletion of the AHR in mice or rats did not markedly
influence the growth of the animals, although a transient retardation during the first few weeks of
postnatal life was reported in mice [9].
However, more recent studies with congenic and genetically bioengineered mouse models have
convincingly demonstrated that the AHR does indeed play an important modulating role in energy
homeostasis. Initially, Kerley-Hamilton et al. [10] reported that when fed on high-fat chow
(“Western diet”) for 28 weeks, male C57BL/6J (B6) mice with a high-affinity AHR (Ahrb1 allele)
became more obese than their congenic counterparts, B6.D2N-Ahrd/J (B6.D2) mice with a low-
affinity AHR (Ahrd allele). The difference in body weight emerged by 17 weeks and broadened
thereafter until the end of the study. At termination, the B6 mice had larger gonadal fat pads,
greater total volume of lipid vacuoles in the liver and higher plasma cholesterol levels than did
B6.D2 mice on the same high-fat diet. Interestingly, however, these differences were not recorded
when the mice were fed regular chow, and they did not appear to result from dissimilar feed
intake levels. Moreover, in B6 mice high-fat diet repressed hepatic Cyp1a2 gene expression by
approximately 3-fold (data on Cyp1a1 were lacking) compared with the standard diet, suggesting
that the canonical AHR signaling pathway was not activated by the special diet. On the other hand,
the expression levels of a wide variety of nuclear receptors were affected by diet and/or genotype
in the liver. In most cases, high-fat diet exhibited a depressing influence in B6 mice, but Pparg
(encoding PPARɣ) was induced by 61% in them. On high-fat diet, a genotype difference was
recorded for Ppara expression [encoding PPARα], which was diminished by 34% in B6 vs. B6.D2
mice [10]. These might have contributed to the outcome because PPARα promotes fatty acid
oxidation in the liver [11] while increased expression of PPARɣ is involved in liver steatosis [12,13].
Impact of global AHR deficiency on diet-induced obesity
Two subsequent studies in which AHR function was affected at the whole animal level
corroborated the role of AHR in dietary obesity. Xu et al. [14] showed that on a high-fat diet, both
AHR-deficient Ahr-/- and hemizygous Ahr+/- mice gained significantly less weight than wildtype mice
from 8 weeks on. Compared with the mutant strains, the wildtype mice had more epididymal and
hepatic fat. The hepatic expression of genes involved in fatty acid translocation (Cd36), lipogenesis
(Fas, Acc), β-oxidation (Cpt1a, Acox1, Ppara), gluconeogenesis (Pck1, G6pc) and glucose oxidation
(Pdk4) was higher in wildtype animals. These also had higher concentrations of insulin and leptin
but lower levels of adiponectin in the serum. The obese wildtype mice displayed glucose
intolerance and insulin insensitivity, whereas both were improved in the mutant strains in line with
their higher serum adiponectin levels. In mice fed the high-fat diet, there was further evidence of
aggravated inflammatory reaction in both the liver and white adipose tissue in the wildtype
animals vs. Ahr-/- and Ahr+/-mice. Again, feed intake was not affected, and neither was locomotor
activity. However, energy expenditure was higher in high-fat-fed Ahr+/- mice than in wildtype mice
on either control or high-fat diet (Ahr-/-mice were not analyzed). This was associated with
enhanced expression of the genes for the primary uncoupling protein (Ucp1) and for the regulator
of mitochondrial biogenesis (Pgc1a) in the brown adipose tissue as well as those for Ppard (a
major regulator of muscle fuel utilization favoring lipid oxidation [15]), Pgc1a, Acox1, Cpt1b, Ucp2
and Ucp3 in skeletal muscle, which may account for the increased energy expenditure. It is
noteworthy that compared with wildtype mice, the Ahr+/-mice expressed approximately 30% of
the AHR mRNA in the liver, and that Cyp1a1 or other AHR battery genes were not influenced by
high-fat diet in wildtype mice [14]. This indicates that even partial elimination of AHR expression
can have a substantial influence on energy homeostasis and that high-fat diet does not seem to
elicit a general AHR activation as measured by expression of genes regulated by it.
Modulation of diet-induced obesity by AHR antagonists
Moyer et al. [16] proved that also pharmacological inhibition of AHR function is capable of
preventing obesity in mice fed on a high-fat diet. Initially, they tested two AHR antagonists, α-
naphtoflavone (aNF) and CH-223191 (approximate doses 3 and 10 mg/kg/day, respectively; added
into diet), and found that during a 5-week exposure, both effectively counteracted the increasing
impacts of high-fat diet on body, fat and liver masses. For CH-223191, the outcome was somewhat
surprising, because this compound has been reported to be a selective antagonist of dioxin-type
AHR agonists [17]. The team next extended the duration of aNF exposure to 26 weeks. In this case,
aNF prevented B6 mice from gaining extra weight on high-fat diet, ameliorated hepatic steatosis
and reduced serum LDL-cholesterol levels. However, it also decelerated the growth of control mice
on regular chow, increased their liver-to-body mass ratio, and caused degenerative changes in
their hepatocytes, indicating liver toxicity of the compound. The researchers then showed that the
gene for indoleamine 2,3-dioxygenase (Ido1), an important tryptophan-metabolizing enzyme, is
required for the full development of high-fat diet-induced obesity in mice. Their additional in vitro
studies revealed that kynurenine rather than kynurenic acid is the probable tryptophan metabolite
to activate the AHR. Furthermore, TGFβ1 (an indirect Ido1 inducer [18] whose hepatic gene
expression is enhanced by high-fat diet [19]) and oxidized LDL (a ligand for toll-like receptors 2 & 4
[20]) stimulated AHR activity, but more slowly than kynurenine or TCDD. Finally, antagonism of
toll-like receptors 2/4 was shown to prevent oxidized LDL-induced AHR activation, while IDO1
inhibition could only diminish it [16]. The effects of a global reduction in AHR activity caused by
genetic or pharmacological means are compiled in Fig. 1.
Liver-specific AHR deficiency and energy balance
In contrast to the amelioration of hepatic steatosis by global AHR deficiency, targeted knockout of
Ahr in hepatocytes exacerbated it in B6 mice fed on a high-fat diet, without interfering with body
weight gain [21]. This appeared to result from augmented expression of genes involved in de novo
lipogenesis such as Srebp1c, Scd1, Acc1 and Gpat1, whereas those related to fatty acid uptake, β-
oxidation or gluconeogenesis were not differentially affected from control mice on the same diet.
High-fat diet-induced hepatic inflammation was also aggravated in knockout mice, coinciding with
reduced induction of Socs3, the gene for a negative regulator of STAT3 (a mediator of cytokine
signaling [22]). Rescue of hepatic Socs3 expression largely reversed the deleterious effects of
hepatic AHR deficiency; the authors further demonstrated Socs3 to be transcriptionally regulated
by the AHR [21]. In two other studies using B6 mice on regular chow, both cholesterol and fatty
acid biosynthesis in the liver were enhanced by hepatocyte-specific ablation of AHR and repressed
by AHR activation (instigated by β-naphtoflavone) through coordinated transcriptional regulation;
the AHR proved to exert these effects by a non-canonical pathway [23,24]. These findings are
illustrated in Fig. 2.
Constitutively active hepatic AHR and energy balance
In FVB mice fed regular chow, the reverse setting, expression of a constitutively active AHR in the
liver (and intestine), also resulted in accumulation of lipids in the liver [25]. While hepatic
trigycerides were increased compared with the wildtype control, hepatic cholesterol and plasma
triglyceride levels were not. Both body and fat mass decreased in the transgenics, whereas lean
body mass was elevated. In the liver, the expression of Ppara and Acox1 was reduced but that of
Cd36 and two fatty acid transporters, Fatp1 and Fatp2, augmented, suggesting enhanced uptake
of fatty acids in the face of their impaired utilization. Moreover, oxidative stress was aggravated
[25].
Adipose tissue-specific AHR deficiency and energy balance
The impact of organ-specific AHR deficiency has also been tested for the adipose tissue. Compared
with wildtype controls, transgenic mice on B6-FVB background, devoid of AHR in mature white
adipocytes and with reduced (by 35%) Ahr expression in the brown adipose tissue, exhibited
increased relative fat mass and decreased relative lean mass, without any difference in body
weight, on standard mouse diet [26]. No effect was found on glucose tolerance but insulin
sensitivity was slightly enhanced. When fed on a high-fat diet, the AHR-deficient mice gained
weight more rapidly than their controls from week 5 on due to enhanced subcutaneous fat
accumulation, but both glucose tolerance and insulin sensitivity remained unchanged (as
measured 4 weeks after an induced weight loss period following 12-week feeding of the high-fat
diet). Relevant to these findings, aNF dose-dependently promoted triglyceride accumulation and
IL-6 secretion in mature murine 3T3-L1 adipocytes in vitro [27]. The reported consequences of
adipose tissue-specific reduction in AHR activity on factors related to energy homeostasis are
summarized in Fig. 3.
Is AHR a protein sensor?
Based on the evidence available at present, AHR signaling is not indispensable for the regulation of
energy homeostasis in the body but rather a modulator whose involvement mainly requires high
energy intake to become manifest. At the whole organism level, the predominant effect appears
to be curtailment of resting energy expenditure in extrahepatic tissues, particularly in brown
adipose tissue and skeletal muscle, although this has yet to be verified by functional
measurements. These two are crucial tissues for adaptive thermogenesis instigated by exposure to
cold or excess dietary energy [28]. In brown adipose tissue, the protein product of Ucp-1 enables
protons to bypass ATP synthase in mitochondria, thus generating heat. It is mainly regulated by
the sympathetic nervous system, the three PPARs and PGC-1α [29]. In skeletal muscle, the
molecular mechanisms of non-shivering thermogenesis are still poorly defined, but major
mediators of fatty acid oxidation and upregulation of energy expenditure in that tissue are PPARδ
and PGC-1α [11,30]. Because in mice harboring adipose tissue-specific AHR deficiency body weight
gain was accelerated on high-fat diet vs. wildtype animals on the same diet, global AHR ablation
might act at a higher regulatory level than the brown adipose tissue itself, i.e. the brain or the
sympathetic nervous system (see Fig. 4). However, it is also possible that the reduction in AHR
activity in the brown adipose tissue was too small to effectively trigger heat generation.
As regards feeding, the ability to dissipate surplus energy in the form of heat is beneficial for
animals if the protein concentration in the food is low, since it allows them then to meet the
adequate protein intake requirement without getting fat. Some of the major dietary activators of
the AHR are related to tryptophan, an essential amino acid, and already a partial impairment of
global AHR function enhances energy expenditure preventing or mitigating obesity. It is thus
conceivable that the AHR’s primary function in energy balance might be to secure sufficient
protein intake by monitoring the levels of an indicator amino acid (tryptophan) and, in case of a
severe shortage of it threatening protein homeostasis, enable overfeeding of calories without the
harmful consequences of substantial overweight such as an impaired ability to escape predators.
This scheme is illustrated in Fig. 4. (Note that reduced AHR activity as such does not increase food
intake.)
Conclusions and future prospects
Considered collectively, the data gleaned hitherto show that AHR functionality is essential for
obesity to develop in full in mice on a high-fat diet. AHR activity appears to critically modulate
energy expenditure at the whole animal level. If AHR function is globally impaired, the adaptive
non-shivering thermogenesis is enhanced in the brown adipose tissue and skeletal muscle to the
extent that obesity can be prevented. Importantly, the AHR need not be totally eliminated for
prevention of obesity, but even partial (70%) reduction will suffice. On the other hand, global and
tissue-specific loss of AHR signaling can have opposite effects on liver fat content and their impact
on insulin sensitivity is also context-dependent.
Regarding whole body energy expenditure, the studies expounded here were all conducted in
mice. It would therefore be of importance to examine (e.g., with the newly generated AHR
knockout rats [31,32]) whether the findings are specific to them or generalizable to other species.
Another issue to address in the future concerns further clarification of the tissues that are
essential to the augmentation of energy expenditure by global AHR functional impairment. In
addition to brown adipose tissue and muscle, the upstream neural regulators of their function (Fig.
4) should be subjected to scrutiny. Nervous system-, brown adipose tissue- and striated muscle-
specific knockouts should help discern whether the effector or the regulatory tissue is critical in
this regard. Finally, a mechanistic key question to address in more detail in the future is the
contribution of canonical and non-canonical AHR signaling pathways to obesity.
It is clear that these findings have implications also for human health, since obesity or being
overweight are currently very common ailments world-wide. In humans, serum AHR ligand
concentrations (total TEQs as measured by a cell-based AHR ligand activity assay or HRGC/HRMS)
have been reported to be associated with the metabolic syndrome, mitochondrial dysfunction and
insulin resistance in Korea [33,34]. Hence, these obesity-related disorders seem to correlate with
AHR activity also in humans, and blocking AHR activity by dietary or pharmacological means might
offer a novel way to treat them. To that end, it is interesting that resveratrol, a natural AHR
antagonist [35] present in red wine, has been shown to cause brown adipose tissue activation and
white fat browning in rodents, albeit at high doses [36]. As global AHR antagonism may result in
untoward side effects such as reduced disease tolerance [37], selective inhibition of AHR function
in the tissue(s) responsible for the protection against obesity should be an important aspect of
future AHR research.
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Legends for the figures
Fig. 1. A synopsis of the interference by a global decrease in AHR activity with diet-induced obesity
and factors related to energy balance in mice. The small arrows depict the direction of change
compared with wildtype mice on the same diet (↔: no change).
Fig. 2. Effect of hepatocyte-specific AHR knockout on some key aspects of energy balance and
metabolism in mice fed on either a high-fat or standard diet. The small arrows depict the direction
of change compared with wildtype mice on the same diet (↔: no change).
Fig. 3. Effect of adipose tissue-specific diminution of AHR activity on some variables related to
energy balance and metabolism in mice fed on either a high-fat or standard diet. The small arrows
depict the direction of change compared with wildtype mice on the same diet (↔: no change).
Fig. 4. Proposed scheme of AHR’s function as a protein sensor. A low protein concentration in food
results in reduced generation of tryptophan metabolites and thereby in lowered AHR activity. This,
in turn, kindles non-shivering thermogenesis in the brown adipose tissue and skeletal muscle. The
augmented energy expenditure enables the animal to overeat energy without getting obese while
satisfying its protein needs. The molecular activation pathway of non-shivering thermogenesis
shown is valid for the brown adipose tissue, for skeletal muscle it is less well defined (molecules in
red: enhanced gene expression recorded in globally AHR-deficient mice on a high-fat feed). The
site at which the reduced activity of the AHR ultimately exerts its action is unknown at present,
but findings in adipose-specific AHR knockout mice suggest that the regulatory systems might be
affected (red arrows with question marks). BAT, brown adipose tissue; NE, norepinephrine (=
noradrenaline); cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; MAPK, mitogen-
activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator
1-alpha; UCP-1, uncoupling protein 1; PPAR, peroxisome proliferator-activated receptor.
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